BEAM [carmustine, etoposide, cytarabine and melphalan] + 131Iodine-Anti-B1 [iodine-131-tositumomab] radioimmunotherapy and autologous hematopoietic stem cell transplantation [HSCT] for the treatment of recurrent non-hodgkin's lymphoma.

Trial Profile

BEAM [carmustine, etoposide, cytarabine and melphalan] + 131Iodine-Anti-B1 [iodine-131-tositumomab] radioimmunotherapy and autologous hematopoietic stem cell transplantation [HSCT] for the treatment of recurrent non-hodgkin's lymphoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 May 2017

At a glance

  • Drugs Iodine-131 tositumomab (Primary) ; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Melphalan
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 01 May 2017 Status changed from active, no longer recruiting to completed.
    • 09 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top